These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27890170)

  • 21. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases.
    Zingarelli S; Airò P; Frassi M; Bazzani C; Scarsi M; Puoti M
    Reumatismo; 2008; 60(1):22-7. PubMed ID: 18432322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.
    Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M
    Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of rheumatic disease with comorbid HBV or HCV infection.
    Vassilopoulos D; Calabrese LH
    Nat Rev Rheumatol; 2012 May; 8(6):348-57. PubMed ID: 22565315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.
    Koutsianas C; Thomas K; Vassilopoulos D
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20912646. PubMed ID: 32206094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines.
    Etienne S; Vosbeck J; Bernsmeier C; Osthoff M
    J Gen Intern Med; 2023 Feb; 38(2):490-501. PubMed ID: 36138278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review.
    Bath RM; Doering BE; Nailor MD; Goodlet KJ
    Ann Pharmacother; 2019 Mar; 53(3):294-310. PubMed ID: 30203666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients with hepatitis B who require immunosuppressive therapy.
    Hwang JP; Lok AS
    Nat Rev Gastroenterol Hepatol; 2014 Apr; 11(4):209-19. PubMed ID: 24247262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO.
    Marignani M; Canzoni M; D'Amelio R; De Santis E; Pecchioli A; Delle Fave G
    Eur J Intern Med; 2011 Dec; 22(6):576-81. PubMed ID: 22075283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.
    King LK; Lee A; Anandacoomarasamy A
    Intern Med J; 2012 May; 42(5):523-31. PubMed ID: 21790927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B Reactivation: A Review of Clinical Guidelines.
    Wang Y; Han SB
    J Clin Gastroenterol; 2021 May-Jun 01; 55(5):393-399. PubMed ID: 33828065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.
    Akiyama S; Cotter TG; Sakuraba A
    World J Gastroenterol; 2021 May; 27(19):2312-2324. PubMed ID: 34040324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?
    Ramos-Casals M
    Nat Rev Rheumatol; 2010 Nov; 6(11):618-20. PubMed ID: 21037559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
    Vassilopoulos D; Calabrese LH
    Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.
    Tavakolpour S; Alavian SM; Sali S
    Hepat Mon; 2016 Apr; 16(4):e35810. PubMed ID: 27257429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.